A study of NUC-3373 in combination with other agents in patients with advanced solid tumours
Research type
Research Study
Full title
A Phase Ib/II open label, multi-arm, parallel cohort dose finding and expansion study to assess the safety, pharmacokinetics and efficacy of NUC-3373, a nucleotide analogue, given in combination with standard approved agents in patients with advanced solid tumours
IRAS ID
1005243
Contact name
Stuart Grant
Contact email
Sponsor organisation
NuCana plc
Eudract number
2022-000722-14
Clinicaltrials.gov Identifier
Research summary
The purpose of this study is to learn more about the effects (safety, effectiveness and tolerability) of a new drug called NUC-3373 in
combination with other medicines that are approved for the treatment of patients with advanced solid tumours. The study will
determine the best dose and schedule of NUC-3373 to be used in combination with these other treatments.There are different parts to this study, known as modules. In all modules, NUC-3373 will be given with an agent called leucovorin
(LV). LV is folinic acid (made from B vitamins) and is given in combination with certain cancer drugs to improve anti-cancer
activity.In Module 1, NUC-3373 + LV will be given to participants with an advanced solid tumour that has returned after previous
treatment with anti-cancer therapies, in combination with pembrolizumab, an immunotherapy drug.In Module 2, NUC-3373 + LV will be given in combination with docetaxel to participants with advanced or metastatic non-small
cell lung cancer (NSCLC) that has returned after previous treatment with other anti-cancer therapies, or who have been unable to
tolerate previous anti-cancer therapies.REC name
West Midlands - Coventry & Warwickshire Research Ethics Committee
REC reference
22/WM/0238
Date of REC Opinion
7 Dec 2022
REC opinion
Further Information Favourable Opinion